Upregulation of human PINK1 gene expression by NFκB signalling

Molecular Brain

Volumn 7, Issue 1, 2014, Pages

  Duan, Xiaoling ^a,b   Tong, Jade ^b   Xu, Qin ^b   Wu, Yili ^a,b   Cai, Fang ^b   Li, Tingyu ^a   Song, Weihong ^a,b  

^a CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Mitochondrial function; NF B; PINK1; Transcription

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME 10 INDUCED PUTATIVE KINASE 1; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; PROTEIN BINDING; PROTEIN KINASE; PTEN-INDUCED PUTATIVE KINASE;

5' UNTRANSLATED REGION; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONSENSUS SEQUENCE; EMBRYO; ENHANCER REGION; GENE DELETION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SWITCHING; GENETIC TRANSCRIPTION; HEK293 CELL LINE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; GENETICS; METABOLISM; MOLECULAR GENETICS;

ANIMALS; BASE SEQUENCE; BINDING SITES; HEK293 CELLS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN KINASES; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; UP-REGULATION;

EID: 84906927371     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/s13041-014-0057-y     Document Type: Article

References (48)

1. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. SK Van Den Eeden, CM Tanner, AL Bernstein, RD Fross, A Leimpeter, DA Bloch, LM Nelson, Am J Epidemiol 2003 157 11 1015 1022 10.1093/aje/kwg068
2. An essay on the shaking palsy. 1817. J Parkinson, J Neuropsychiatry Clin Neurosci 2002 14 2 223 236 discussion 222
3. Parkinson's disease: genetics and pathogenesis. JM Shulman, PL De Jager, MB Feany, Annu Rev Pathol 2011 6 193 222 10.1146/annurev-pathol-011110-130242
4. Paralysis agitans. I. Pathologische anatomie. F Lewy, Handbuch der Neurologie 1912 3 920 933
5. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. M Unoki, Y Nakamura, Oncogene 2001 20 33 4457 4465 10.1038/sj.onc.1204608
6. Characterization of PINK1 processing, stability, and subcellular localization. W Lin, UJ Kang, J Neurochem 2008 106 1 464 474 10.1111/j.1471-4159.2008.05398.x
7. Cytoplasmic localization and proteasomal degradation of N-terminally cleaved form of PINK1. S Takatori, G Ito, T Iwatsubo, Neurosci Lett 2008 430 1 13 17 10.1016/j.neulet.2007.10.019
8. Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. AW Greene, K Grenier, MA Aguileta, S Muise, R Farazifard, ME Haque, HM McBride, DS Park, EA Fon, EMBO Rep 2012 13 4 378 385 10.1038/embor.2012.14
9. Cytosolic cleaved PINK1 represses Parkin translocation to mitochondria and mitophagy. MA Fedorowicz, RL de Vries-Schneider, C Rub, D Becker, Y Huang, C Zhou, DM Alessi Wolken, W Voos, Y Liu, S Przedborski, EMBO Rep 2014 15 1 86 93 10.1002/embr.201337294
10. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. H Xiong, D Wang, L Chen, YS Choo, H Ma, C Tang, K Xia, W Jiang, Z Ronai, X Zhuang, Z Zhang, J Clin Invest 2009 119 3 650 660 10.1172/JCI37617
11. Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function. VA Morais, P Verstreken, A Roethig, J Smet, A Snellinx, M Vanbrabant, D Haddad, C Frezza, W Mandemakers, D Vogt-Weisenhorn, R Van Coster, W Wurst, L Scorrano, B De Strooper, EMBO Mol Med 2009 1 2 99 111 10.1002/emmm.200900006
12. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. EM Valente, PM Abou-Sleiman, V Caputo, MM Muqit, K Harvey, S Gispert, Z Ali, D Del Turco, AR Bentivoglio, DG Healy, A Albanese, R Nussbaum, R Gonzalez-Maldonado, T Deller, S Salvi, P Cortelli, WP Gilks, DS Latchman, RJ Harvey, B Dallapiccola, G Auburger, NW Wood, Science 2004 304 5674 1158 1160 10.1126/science.1096284
13. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. EM Valente, AR Bentivoglio, PH Dixon, A Ferraris, T Ialongo, M Frontali, A Albanese, NW Wood, Am J Hum Genet 2001 68 4 895 900 10.1086/319522
14. Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS-mediated NF-kappaB and JNK signaling. N Shembade, NS Harhaj, DJ Liebl, EW Harhaj, EMBO J 2007 26 17 3910 3922 10.1038/sj.emboj.7601823
15. Expanding role of ubiquitination in NF-kappaB signaling. S Liu, ZJ Chen, Cell Res 2011 21 1 6 21 10.1038/cr.2010.170
16. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. M Mogi, T Kondo, Y Mizuno, T Nagatsu, Neurosci Lett 2007 414 1 94 97 10.1016/j.neulet.2006.12.003
17. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. S Hunot, B Brugg, D Ricard, PP Michel, MP Muriel, M Ruberg, BA Faucheux, Y Agid, EC Hirsch, Proc Natl Acad Sci U S A 1997 94 14 7531 7536 10.1073/pnas.94.14.7531
18. The involvement of NF-kappaB p65/p52 in the effects of GDNF on DA neurons in early PD rats. JP Cao, HJ Wang, JK Yu, HM Liu, DS Gao, Brain Res Bull 2008 76 5 505 511 10.1016/j.brainresbull.2008.03.007
19. Inhibition of GSK3beta-mediated BACE1 expression reduces Alzheimer-associated phenotypes. PT Ly, Y Wu, H Zou, R Wang, W Zhou, A Kinoshita, M Zhang, Y Yang, F Cai, J Woodgett, W Song, J Clin Invest 2013 123 1 224 235 10.1172/JCI64516
20. Increased NF-kappaB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. CH Chen, W Zhou, S Liu, Y Deng, F Cai, M Tone, Y Tone, Y Tong, W Song, Int J Neuropsychopharmacol 2012 15 01 77 90 10.1017/S1461145711000149
21. Regulator of calcineurin 1 gene transcription is regulated by nuclear factor-kappaB. L Zheng, H Liu, P Wang, W Song, X Sun, Curr Alzheimer Res 2014 11 2 156 164 10.2174/1567205010666131212114907
22. NF-kappaB signaling inhibits ubiquitin carboxyl-terminal hydrolase L1 gene expression. R Wang, M Zhang, W Zhou, PT Ly, F Cai, W Song, J Neurochem 2011 116 6 1160 1170 10.1111/j.1471-4159.2011.07172.x
23. Transcriptional regulation of human USP24 gene expression by NF-kappa B. K Wang, S Liu, J Wang, Y Wu, F Cai, W Song, J Neurochem 2014 128 6 818 828 10.1111/jnc.12626
24. NF-kappaB activity is inversely correlated to RNF11 expression in Parkinson's disease. E Pranski, CD Van Sanford, N Dalal, AL Orr, D Karmali, DS Cooper, M Gearing, JJ Lah, AI Levey, R Betarbet, Neurosci Lett 2013 547 16 20 10.1016/j.neulet.2013.04.056
25. Generation of stably transfected Mammalian cell lines as fluorescent screening assay for NF-kappaB activation-dependent gene expression. CE Hellweg, C Baumstark-Khan, G Horneck, J Biomol Screen 2003 8 5 511 521
26. Wu Z, Zhu Y, Cao X, Sun S, Zhao B: Mitochondrial toxic effects of abeta through mitofusins in the early pathogenesis of alzheimer's disease. Mol Neurobiol 2014. (Epub ahead of printing) PMID:24710686.
27. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. S Hauptmann, I Scherping, S Drose, U Brandt, KL Schulz, M Jendrach, K Leuner, A Eckert, WE Muller, Neurobiol Aging 2009 30 10 1574 1586 10.1016/j.neurobiolaging.2007.12.005
28. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. PH Reddy, Exp Neurol 2009 218 2 286 292 10.1016/j.expneurol.2009.03.042
29. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. G Aliev, HH Palacios, B Walrafen, AE Lipsitt, ME Obrenovich, L Morales, Int J Biochem Cell Biol 2009 41 10 1989 2004 10.1016/j.biocel.2009.03.015
30. Tumor necrosis factor-alpha impairs oligodendroglial differentiation through a mitochondria-dependent process. M Bonora, E De Marchi, S Patergnani, JM Suski, F Celsi, A Bononi, C Giorgi, S Marchi, A Rimessi, J Duszynski, T Pozzan, MR Wieckowski, P Pinton, Cell Death Differ 2014 21 1198 1208 10.1038/cdd.2014.35
31. Mitochondria in multiple sclerosis. P Ghafourifar, K Mousavizadeh, MS Parihar, RR Nazarewicz, A Parihar, WJ Zenebe, Front Biosci 2008 13 3116 3126 10.2741/2913
32. The ubiquitin pathway in Parkinson's disease. E Leroy, R Boyer, G Auburger, B Leube, G Ulm, E Mezey, G Harta, MJ Brownstein, S Jonnalagada, T Chernova, A Dehejia, C Lavedan, T Gasser, PJ Steinbach, KD Wilkinson, MH Polymeropoulos, Nature 1998 395 6701 451 452 10.1038/26652
33. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. C Paisan-Ruiz, S Jain, EW Evans, WP Gilks, J Simon, M van der Brug, A Lopez de Munain, S Aparicio, AM Gil, N Khan, J Johnson, JR Martinez, D Nicholl, IM Carrera, AS Pena, R de Silva, A Lees, JF Marti-Masso, J Perez-Tur, NW Wood, AB Singleton, Neuron 2004 44 4 595 600 10.1016/j.neuron.2004.10.023
34. PINK1 mutations are associated with sporadic early-onset parkinsonism. EM Valente, S Salvi, T Ialongo, R Marongiu, AE Elia, V Caputo, L Romito, A Albanese, B Dallapiccola, AR Bentivoglio, Ann Neurol 2004 56 3 336 341 10.1002/ana.20256
35. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. T Kitada, S Asakawa, N Hattori, H Matsumine, Y Yamamura, S Minoshima, M Yokochi, Y Mizuno, N Shimizu, Nature 1998 392 6676 605 608 10.1038/33416
36. PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. C Criscuolo, G Volpe, A De Rosa, A Varrone, R Marongiu, P Mancini, E Salvatore, B Dallapiccola, A Filla, C Valente EM Criscuolo, G Volpe, A De Rosa, A Varrone, R Marongiu, P Mancin, E Salvatore, B Dallapiccola, A Filla, EM Valente, G De Michele, Movement disorders: official journal of the Movement Disorder Society 2006 21 8 1265 1267 10.1002/mds.20933
37. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. CA Gautier, T Kitada, J Shen, Proc Natl Acad Sci U S A 2008 105 32 11364 11369 10.1073/pnas.0802076105
38. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. X Wang, D Winter, G Ashrafi, J Schlehe, YL Wong, D Selkoe, S Rice, J Steen, MJ LaVoie, TL Schwarz, Cell 2011 147 4 893 906 10.1016/j.cell.2011.10.018
39. Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease. R Tufi, S Gandhi, IP de Castro, S Lehmann, PR Angelova, D Dinsdale, E Deas, H Plun-Favreau, P Nicotera, AE Abramov AY Willis, GR Mallucci, SH Loh, LM Martins, Nat Cell Biol 2014 16 2 157 166 10.1038/ncb2901
40. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. MA Christensen, W Zhou, H Qing, A Lehman, S Philipsen, W Song, Mol Cell Biol 2004 24 2 865 874 10.1128/MCB.24.2.865-874.2004
41. Transcriptional regulation of TMP21 by NFAT. S Liu, S Zhang, K Bromley-Brits, F Cai, W Zhou, K Xia, J Mittelholtz, W Song, Mol Neurodegeneration 2011 6 21 10.1186/1750-1326-6-21
42. PINK1 cleavage at position A103 by the mitochondrial protease PARL. E Deas, H Plun-Favreau, S Gandhi, H Desmond, S Kjaer, SH Loh, AE Renton, RJ Harvey, AJ Whitworth, LM Martins, AY Abramov, NW Wood, Hum Mol Genet 2011 20 5 867 879 10.1093/hmg/ddq526
43. PINK1 overexpression protects against C2-ceramide-induced CAD cell death through the PI3K/AKT pathway. RM Sanchez-Mora, H Arboleda, G Arboleda, J Mol Neurosci 2012 47 3 582 594 10.1007/s12031-011-9687-z
44. Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. MM Muqit, PM Abou-Sleiman, AT Saurin, K Harvey, S Gandhi, E Deas, S Eaton, MD Payne Smith, K Venner, A Matilla, DG Healy, WP Gilks, AJ Lees, J Holton, T Revesz, PJ Parker, RJ Harvey, NW Wood, DS Latchman, J Neurochem 2006 98 1 156 169 10.1111/j.1471-4159.2006.03845.x
45. PINK1 protein in normal human brain and Parkinson's disease. S Gandhi, MM Muqit, L Stanyer, DG Healy, PM Abou-Sleiman, I Hargreaves, S Heales, M Ganguly, L Parsons, AJ Lees, DS Latchman, JL Holton, NW Wood, T Revesz, Brain 2006 129 Pt 7 1720 1731 10.1093/brain/awl114
46. PINK1, a gene product of PARK6, accumulates in alpha-synucleinopathy brains. T Murakami, Y Moriwaki, T Kawarabayashi, M Nagai, Y Ohta, K Deguchi, T Kurata, N Morimoto, Y Takehisa, E Matsubara, M Ikeda, Y Harigaya, M Shoji, R Takahashi, K Abe, J Neurol Neurosurg Psychiatry 2007 78 6 653 654 10.1136/jnnp.2006.100123
47. Degradation of BACE by the ubiquitin-proteasome pathway. H Qing, W Zhou, MA Christensen, X Sun, Y Tong, W Song, Faseb J 2004 18 13 1571 1573
48. Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1. Z Zhang, P Nadeau, W Song, D Donoviel, M Yuan, A Bernstein, BA Yankner, Nat Cell Biol 2000 2 7 463 465 10.1038/35017108